Treatment Variation in Older Adults With Differentiated Thyroid Cancer

被引:4
|
作者
Sutton, Whitney [1 ]
Canner, Joseph K. [1 ]
Segev, Dorry L. [1 ]
Zeiger, Martha A. [2 ]
Mathur, Aarti [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Surg, 600 North Wolfe St,Blalock 606, Baltimore, MD 21287 USA
[2] NCI, Dept Surg Oncol, NIH, Bethesda, MD 20892 USA
关键词
Thyroid cancer; Aging; Thyroidectomy; Disease-specific mortality; ASSOCIATION MANAGEMENT GUIDELINES; UNITED-STATES; YOUNG AGE; PAPILLARY; SURVIVAL; PREDICTORS; PROGNOSIS; MORTALITY; NODULES; PATIENT;
D O I
10.1016/j.jss.2020.04.013
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: The growth of the aging population coupled with the increasing incidence of thyroid cancer warrants a better understanding of thyroid cancer in older adults. We aimed to investigate the variation of treatment patterns and determine if the extent of surgery is associated with disease-specific mortality in older adults with differentiated thyroid cancer (DTC). Methods: We performed a population-based study using the Surveillance, Epidemiology, and End Results 18 program to examine patients diagnosed with DTC between 2004 and 2015. Patients were stratified by age: younger adults (aged 18-54 y), middle adults (aged 5564 y), older adults (aged 65-79 y), and super elderly (aged >= 80 y). Disease-specific mortality was estimated using Kaplan-Meier curves and compared using the log-rank test. Multi variable Cox regression was used to assess associations between clinicopathologic characteristics and treatment patterns on disease-specific mortality. Results: Of 117,098 patients with DTC, 72,368 were younger adults, 23,726 middle adults, 18,119 older adults, and 2885 were super elderly. In patients with DTC, compared with younger adults, fewer middle, older, and super elderly adults underwent any surgery (99.0%, 98.4%, 97.4%, and 89.1%, respectively; P < 0.001) or received radioactive iodine (RAI; 48.7%, 42.5%, 39.7%, and 30.7%, respectively; P < 0.001). Furthermore, middle, older, and super elderly adults had higher risk of mortality from DTC (hazard ratio [HR]: 4.0, 95% confidence interval [CI]: 3.2-4.8, P < 0.001; HR: 7.6, 95% CI: 6.3-9.1, P < 0.001; and HR: 17.2, 95% CI: 13.8-21.3, P < 0.001, respectively). On multivariable Cox regression while adjusting for clinicopathologic confounders, management was a significant prognostic factor (no surgery HR: 3.8, 95% CI: 3.1-4.6, P < 0.001; and RAI HR: 0.7, 95% CI: 0.6-0.8, P < 0.001). Conclusions: In patients with DTC, fewer older adults (>= 65 y) underwent surgery or treatment with RAI, and this was associated with a worse disease-specific survival. Surgical decision-making in the older population is complex, and future prospective studies are needed to assess this age-related treatment variation. (c) 2020 Elsevier Inc. All rights reserved.
引用
收藏
页码:154 / 164
页数:11
相关论文
共 50 条
  • [41] Updated recommendations for the diagnosis and treatment of differentiated thyroid cancer
    Nikola, Besic
    Alenka, Grosel
    Andraz, Perhavec
    Andrej, Doma
    Andreja, Schwarzbarti-Pevec
    Andreja, Klevisar Ivancic
    Andrej, Vogrin
    Barbara, Vidergar-Kralj
    Barbara, Gazic
    Barbara, Peric
    Biaz, Krhin
    Cvetka, Grasic Kuhar
    Edvard, Prinat
    Ivana, Zagar
    Jerca, Blazina
    Katarina, Zevnik
    Katica, Bajuk Studen
    Katja, Zaletel
    Maragareta, Strojan Flezar
    Marko, Hocevar
    Marko, Kokalj
    Marta, Dremeilj
    Nebojsa, Glumac
    Olga, Blatnik
    Simona, Gaberscek
    Snezana, Pavlovic Dokic
    Ulrika, Klopcic
    Veronika, Kloboves-Prevodnik
    Zorica, Cekic
    ONKOLOGIJA, 2022, 26 (01) : 76 - 106
  • [42] Quantitative radioiodine therapy in the treatment of differentiated thyroid cancer
    Maxon, HR
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE, 1999, 43 (04): : 313 - 323
  • [43] Controversies in the Radioiodine Treatment of Patients With Differentiated Thyroid Cancer
    Buscombe, John
    SEMINARS IN NUCLEAR MEDICINE, 2023, 53 (04) : 475 - 480
  • [44] Multimodal treatment of bony metastases in differentiated thyroid cancer
    Pezzullo, L
    Caracò, C
    Fazioli, F
    Salati, N
    Ionna, F
    Mozzillo, N
    BRITISH JOURNAL OF SURGERY, 1998, 85 : 61 - 61
  • [45] Lenvatinib: an investigational agent for the treatment of differentiated thyroid cancer
    Ferrari, Silvia Martina
    Elia, Giusy
    Ragusa, Francesca
    Paparo, Sabrina Rosaria
    Mazzi, Valeria
    Miccoli, Mario
    Galdiero, Maria Rosaria
    Varricchi, Gilda
    Foddis, Rudy
    Guglielmi, Giovanni
    Spinelli, Claudio
    La Motta, Concettina
    Benvenga, Salvatore
    Antonelli, Alessandro
    Fallahi, Poupak
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2021, 30 (09) : 913 - 921
  • [46] Novel treatment strategy for advanced differentiated thyroid cancer
    Kiyota, Naomi
    ANNALS OF ONCOLOGY, 2021, 32 : S274 - S274
  • [47] New Insight into the Treatment of Advanced Differentiated Thyroid Cancer
    Safavi, Arash
    Vijayasekaran, Aparna
    Guerrero, Marlon A.
    JOURNAL OF THYROID RESEARCH, 2012, 2012
  • [48] Indications and results of radioiodine treatment of differentiated thyroid cancer
    Riemann, B.
    CHIRURG, 2020, 91 (12): : 1013 - 1016
  • [49] Update on radiactive iodine treatment of differentiated thyroid cancer
    Tamayo-Alonso, Pilar
    Martin-Gomez, Esther
    Garcia-Talavera, Paloma
    Canadas-Salazar, Jose
    Penaherrera-Cepeda, Carolina
    Diaz-Gonzalez, Luis
    REVISTA ORL, 2021, 12 (04) : 371 - 380
  • [50] Radioiodine treatment of well-differentiated thyroid cancer
    Wartofsky, Leonard
    Van Nostrand, Douglas
    ENDOCRINE, 2012, 42 (03) : 506 - 513